Sales slid 9% during the second quarter, with generic Avapro and Plavix inflicting financial pain. The company says it is going to invest more to promote Eliquis among HCPs and plans on deploying a wider diabetes sales force.
Studies provide more clues to patient adherence, medical needs
A Data and Safety Monitoring Board recommendation has wiped aleglitazar from the drug maker’s slate of possible diabetes medications.
Business briefs: Onyx, Pfizer, Covidien
July 1, 2013
5:58 pm
Onyx says no to Amgen bid, yes to other options; Pfizer/BMS may be able to expand Eliquis appeal; Covidien officially divides into two.
Business briefs: Astellas, ADA, AJMC, AARP
June 25, 2013
4:25 pm
Astellas teams up with Cytokinetics for muscle weakness research; ADA says lifestyle changes don’t protect diabetics’ hearts; AJMC talks pharmacists as diabetes counselors; and AARP helps with healthcare reform education.
Business briefs: Medtronic, AMA, Komen, GSK, Lilly, AZN
June 18, 2013
4:50 pm
Studies undercut Medtronic spine treatment benefit, AMA wars over obesity classification, Komen gets a new CEO, GSK offloads thrombosis meds, Lilly gains diabetes treatment, AZN chooses new site
Business briefs: Boehringer Ingelheim, Teva, Medicare
June 12, 2013
5:03 pm
Good and bad news about Pradaxa; Plan B decision not deemed a big threat to Teva’s sales; Study says Medicare patients more likely to receive brand-name medications than VA patients